{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li H"],"funding":["CAMS Innovation Fund for Medical Sciences","National Natural Science Foundation, China","National Mega-Project for “R&amp;D for Innovative drugs”, Ministry of Science and Technology, China"],"pagination":["e039700"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7722377"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(12)"],"pubmed_abstract":["<h4>Objective</h4>Non-alcoholic fatty liver disease (NAFLD) is a global epidemic without effective therapeutic agents in the clinic. This meta-analysis aimed to assess the efficacy of the marketed hepatoprotectant bicyclol at improving blood biomarkers in patients with NAFLD.<h4>Design</h4>Electronic databases were searched for randomised controlled trials (RCTs) published up to August 2020 using bicyclol to treat NAFLD. The risk of bias, quality of evidence and publication bias were evaluated. Blood biomarkers, including alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), triglyceride (TG) and total cholesterol (TC), were analysed using Review Manager V.5.3 software. Outcomes with significant heterogeneity (I<sup>2</sup> ≥75%) were divided into the bicycl"],"journal":["BMJ open"],"pubmed_title":["Effect of bicyclol on blood biomarkers of NAFLD: a systematic review and meta-analysis."],"pmcid":["PMC7722377"],"funding_grant_id":["2019-I2M-1-001","81621064","2018ZX09711001-003-010"],"pubmed_authors":["Li H","Liu NN","Peng ZG"],"additional_accession":[]},"is_claimable":false,"name":"Effect of bicyclol on blood biomarkers of NAFLD: a systematic review and meta-analysis.","description":"<h4>Objective</h4>Non-alcoholic fatty liver disease (NAFLD) is a global epidemic without effective therapeutic agents in the clinic. This meta-analysis aimed to assess the efficacy of the marketed hepatoprotectant bicyclol at improving blood biomarkers in patients with NAFLD.<h4>Design</h4>Electronic databases were searched for randomised controlled trials (RCTs) published up to August 2020 using bicyclol to treat NAFLD. The risk of bias, quality of evidence and publication bias were evaluated. Blood biomarkers, including alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), triglyceride (TG) and total cholesterol (TC), were analysed using Review Manager V.5.3 software. Outcomes with significant heterogeneity (I<sup>2</sup> ≥75%) were divided into the bicycl","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2025-04-26T05:13:21.008Z","creation":"2021-02-20T10:33:18Z"},"accession":"S-EPMC7722377","cross_references":{"pubmed":["33277283"],"doi":["10.1136/bmjopen-2020-039700"]}}